Cannabinoid-Based Drugs Seek New High, Part II
Developers Anticipate Additional Approvals after FDA Nod for Epidiolex
CAR T Cells Show Solid Progress
Tumors are Being Deprived of Cover by New CAR T-Cell Technologies
Another "CRISPR Calamity"? U.K. Team Reports CRISPR-Induced Gene Rearrangements
New Findings Call the Precision of CRISPR-Cas9 Gene Editing into Question
Organs-on-Chips Take Flight
Initiative to Use Technology Aboard International Space Station Set to Begin
For full access to this article login to GEN Select now.
Synthetic Bio Not Yet Ready for the Market
Lab-Designed Calls and Pathways Take Genetic and Metabolic Engineering to Next Level
- In May of this year, the J. Craig Venter Institute (JCVI) announced it had created the first fully synthetic, self-replicating bacterial cell ( Mycoplasma nycoides JCVI-syn1.0). While this proof-of-concept demonstration of an “artificial life form” might raise justifiable fears about the dangers of unregulated or nefarious synthetic biology efforts, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.